Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
22 /100
LOW RISK
Score updated Sep 12, 2026

BCRX — BioCryst Pharmaceuticals, Inc. Dilution Risk Tracker

Track BCRX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track BCRX — Get alerts when the score changes →

As of September 12, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) has a DilutionWatch DilutionScore of 22/100, rated LOW dilution risk. BioCryst Pharmaceuticals, Inc. has a market capitalization of $2.26B, 255.54M shares outstanding, 302 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
22
💰 Cash Runway
25
📊 Float Risk
7
⚠️ Warrant Exposure
15
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for BCRX.
🔔 Track BCRX — Get forecast alerts →

Market Data

Market Cap$2.26B
Shares Outstanding255.54M
Float220.86M
Cash$352.57M
Debt$395.40M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore22/100DilutionWatch score record
Shares Outstanding255.54MVerified float table or market cache
Public Float220.86MVerified float table or market cache
Market Cap$2.26BMarket data cache
Cash Runway22.2 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 5.

Recent SEC source mix: 4 5.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 39.6% shares (2026Q1 vs prior)
302 institutional holders · 298.82M shares
#1 BlackRock, Inc. 22.65M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 22.27M shares
#3 JANUS HENDERSON GROUP PLC 17.82M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest34.05M
Days to Cover14.4
% of Float15.4%
FINRA data as of Aug 31, 2026

Recent SEC Activity

4 INSIDER TRANSACTION 2026-09-02
4 INSIDER TRANSACTION 2026-09-02
4 INSIDER TRANSACTION 2026-09-02
4 INSIDER TRANSACTION 2026-09-02
4 INSIDER TRANSACTION 2026-09-02
Full SEC filing analysis available with free account

Recent News

No recent news

Factual BCRX Dilution Snapshot

BioCryst Pharmaceuticals, Inc. (BCRX) has a DilutionScore of 22/100, rated Low dilution risk. Score date: September 12, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track BCRX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking BCRX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,348+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for BCRX
BCRX FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.